Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Megha SANTHOSH |
Documents disponibles écrits par cet auteur (2)
Faire une suggestion Affiner la recherche
Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials / Logan SHURTZ in Autism, 27-4 (May 2023)
[article]
Titre : Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials Type de document : Texte imprimé et/ou numérique Auteurs : Logan SHURTZ, Auteur ; Chloe SCHWARTZ, Auteur ; Charlotte DISTEFANO, Auteur ; James C MCPARTLAND, Auteur ; April R LEVIN, Auteur ; Geraldine DAWSON, Auteur ; Natalia M KLEINHANS, Auteur ; Susan FAJA, Auteur ; Sara J WEBB, Auteur ; Frederick SHIC, Auteur ; Adam J NAPLES, Auteur ; Helen SEOW, Auteur ; Raphael A BERNIER, Auteur ; Katarzyna CHAWARSKA, Auteur ; Catherine A SUGAR, Auteur ; James DZIURA, Auteur ; Damla SENTURK, Auteur ; Megha SANTHOSH, Auteur ; Shafali S JESTE, Auteur Article en page(s) : p.952-966 Langues : Anglais (eng) Mots-clés : aberrant behavior checklist,antipsychotics,autism spectrum disorders,clinical trials,medications,Vineland Adaptive Behavior Scales Index. décimale : PER Périodiques Résumé : Children with autism spectrum disorder are prescribed various medications to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity and prevent contamination of clinical endpoints. However, this choice may compromise the representativeness of the sample. In a recent study designed to identify biomarkers and endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, providing the opportunity to examine characteristics of psychotropic medication use and guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the study and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Our findings suggest that exclusion of children taking concomitant psychotropic medications could limit the representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options.Lay abstractChildren with autism spectrum disorder are prescribed a variety of medications that affect the central nervous system (psychotropic medications) to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity of the sample and prevent contamination of biomarkers or clinical endpoints. However, this choice may significantly diminish the clinical representativeness of the sample. In a recent multisite study designed to identify biomarkers and behavioral endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, thus providing a unique opportunity to examine characteristics of psychotropic medication use in a research cohort and to guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the ABC-CT and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half of these children. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Descriptive analysis showed that children taking antipsychotics displayed a trend toward greater overall impairment. Our findings suggest that exclusion of children taking concomitant psychotropic medications in trials could limit the clinical representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options. En ligne : https://doi.org/10.1177/13623613221121425 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=499
in Autism > 27-4 (May 2023) . - p.952-966[article] Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials [Texte imprimé et/ou numérique] / Logan SHURTZ, Auteur ; Chloe SCHWARTZ, Auteur ; Charlotte DISTEFANO, Auteur ; James C MCPARTLAND, Auteur ; April R LEVIN, Auteur ; Geraldine DAWSON, Auteur ; Natalia M KLEINHANS, Auteur ; Susan FAJA, Auteur ; Sara J WEBB, Auteur ; Frederick SHIC, Auteur ; Adam J NAPLES, Auteur ; Helen SEOW, Auteur ; Raphael A BERNIER, Auteur ; Katarzyna CHAWARSKA, Auteur ; Catherine A SUGAR, Auteur ; James DZIURA, Auteur ; Damla SENTURK, Auteur ; Megha SANTHOSH, Auteur ; Shafali S JESTE, Auteur . - p.952-966.
Langues : Anglais (eng)
in Autism > 27-4 (May 2023) . - p.952-966
Mots-clés : aberrant behavior checklist,antipsychotics,autism spectrum disorders,clinical trials,medications,Vineland Adaptive Behavior Scales Index. décimale : PER Périodiques Résumé : Children with autism spectrum disorder are prescribed various medications to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity and prevent contamination of clinical endpoints. However, this choice may compromise the representativeness of the sample. In a recent study designed to identify biomarkers and endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, providing the opportunity to examine characteristics of psychotropic medication use and guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the study and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Our findings suggest that exclusion of children taking concomitant psychotropic medications could limit the representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options.Lay abstractChildren with autism spectrum disorder are prescribed a variety of medications that affect the central nervous system (psychotropic medications) to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity of the sample and prevent contamination of biomarkers or clinical endpoints. However, this choice may significantly diminish the clinical representativeness of the sample. In a recent multisite study designed to identify biomarkers and behavioral endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, thus providing a unique opportunity to examine characteristics of psychotropic medication use in a research cohort and to guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the ABC-CT and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half of these children. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Descriptive analysis showed that children taking antipsychotics displayed a trend toward greater overall impairment. Our findings suggest that exclusion of children taking concomitant psychotropic medications in trials could limit the clinical representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options. En ligne : https://doi.org/10.1177/13623613221121425 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=499 Frontal EEG alpha asymmetry in youth with autism: Sex differences and social-emotional correlates / Megha SANTHOSH ; Anna KRESSE ; Elizabeth AYLWARD ; Raphael BERNIER ; Susan BOOKHEIMER ; Shafali JESTE ; Allison JACK ; James C. MCPARTLAND ; Adam NAPLES ; John D. VAN HORN ; Kevin PELPHREY ; Sara Jane WEBB ; ACE GENDAAR NETWORK in Autism Research, 16-12 (December 2023)
[article]
Titre : Frontal EEG alpha asymmetry in youth with autism: Sex differences and social-emotional correlates Type de document : Texte imprimé et/ou numérique Auteurs : Megha SANTHOSH, Auteur ; Anna KRESSE, Auteur ; Elizabeth AYLWARD, Auteur ; Raphael BERNIER, Auteur ; Susan BOOKHEIMER, Auteur ; Shafali JESTE, Auteur ; Allison JACK, Auteur ; James C. MCPARTLAND, Auteur ; Adam NAPLES, Auteur ; John D. VAN HORN, Auteur ; Kevin PELPHREY, Auteur ; Sara Jane WEBB, Auteur ; ACE GENDAAR NETWORK, Auteur Article en page(s) : p.2364-2377 Index. décimale : PER Périodiques Résumé : Abstract In youth broadly, EEG frontal alpha asymmetry (FAA) associates with affective style and vulnerability to psychopathology, with relatively stronger right activity predicting risk for internalizing and externalizing behaviors. In autistic youth, FAA has been related to ASD diagnostic features and to internalizing symptoms. Among our large, rigorously characterized, sex-balanced participant group, we attempted to replicate findings suggestive of altered FAA in youth with an ASD diagnosis, examining group differences and impact of sex assigned at birth. Second, we examined relations between FAA and behavioral variables (ASD features, internalizing, and externalizing) within autistic youth, examining effects by sex. Third, we explored whether the relation between FAA, autism features, and mental health was informed by maternal depression history. In our sample, FAA did not differ by diagnosis, age, or sex. However, youth with ASD had lower total frontal alpha power than youth without ASD. For autistic females, FAA and bilateral frontal alpha power correlated with social communication features, but not with internalizing or externalizing symptoms. For autistic males, EEG markers correlated with social communication features, and with externalizing behaviors. Exploratory analyses by sex revealed further associations between youth FAA, behavioral indices, and maternal depression history. In summary, findings suggest that individual differences in FAA may correspond to social-emotional and mental health behaviors, with different patterns of association for females and males with ASD. Longitudinal consideration of individual differences across levels of analysis (e.g., biomarkers, family factors, and environmental influences) will be essential to parsing out models of risk and resilience among autistic youth. En ligne : https://doi.org/10.1002/aur.3032 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=518
in Autism Research > 16-12 (December 2023) . - p.2364-2377[article] Frontal EEG alpha asymmetry in youth with autism: Sex differences and social-emotional correlates [Texte imprimé et/ou numérique] / Megha SANTHOSH, Auteur ; Anna KRESSE, Auteur ; Elizabeth AYLWARD, Auteur ; Raphael BERNIER, Auteur ; Susan BOOKHEIMER, Auteur ; Shafali JESTE, Auteur ; Allison JACK, Auteur ; James C. MCPARTLAND, Auteur ; Adam NAPLES, Auteur ; John D. VAN HORN, Auteur ; Kevin PELPHREY, Auteur ; Sara Jane WEBB, Auteur ; ACE GENDAAR NETWORK, Auteur . - p.2364-2377.
in Autism Research > 16-12 (December 2023) . - p.2364-2377
Index. décimale : PER Périodiques Résumé : Abstract In youth broadly, EEG frontal alpha asymmetry (FAA) associates with affective style and vulnerability to psychopathology, with relatively stronger right activity predicting risk for internalizing and externalizing behaviors. In autistic youth, FAA has been related to ASD diagnostic features and to internalizing symptoms. Among our large, rigorously characterized, sex-balanced participant group, we attempted to replicate findings suggestive of altered FAA in youth with an ASD diagnosis, examining group differences and impact of sex assigned at birth. Second, we examined relations between FAA and behavioral variables (ASD features, internalizing, and externalizing) within autistic youth, examining effects by sex. Third, we explored whether the relation between FAA, autism features, and mental health was informed by maternal depression history. In our sample, FAA did not differ by diagnosis, age, or sex. However, youth with ASD had lower total frontal alpha power than youth without ASD. For autistic females, FAA and bilateral frontal alpha power correlated with social communication features, but not with internalizing or externalizing symptoms. For autistic males, EEG markers correlated with social communication features, and with externalizing behaviors. Exploratory analyses by sex revealed further associations between youth FAA, behavioral indices, and maternal depression history. In summary, findings suggest that individual differences in FAA may correspond to social-emotional and mental health behaviors, with different patterns of association for females and males with ASD. Longitudinal consideration of individual differences across levels of analysis (e.g., biomarkers, family factors, and environmental influences) will be essential to parsing out models of risk and resilience among autistic youth. En ligne : https://doi.org/10.1002/aur.3032 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=518